ホーム > 市場調査レポート > 医薬品

市場調査レポート

商品コード

1507090

マンノースリン酸イソメラーゼ (MPI) 欠損症：洞察・疫学・市場予測 (～2034年)

Mannose Phosphate Isomerase (MPI) Deficiency - Market Insight, Epidemiology, and Market Forecast - 2034

出版日: 2024年06月01日
発行: DelveInsight医薬品関連専門
ページ情報: 英文 200 Pages
納期: 2～10営業日

カスタマイズ可能

適宜更新あり

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の主要7カ国におけるマンノースリン酸イソメラーゼ (MPI) 欠損症の市場を調査し、疾患の背景・概要、疫学、治療と管理の概要、市場促進要因と障壁、アンメットニーズ、上市薬およびパイプライン薬のプロファイル、主要国の市場規模の推移・予測、競合情勢などをまとめ、最良の機会を発掘し、市場の潜在力を評価します。

対象地域

米国
欧州5カ国（ドイツ・フランス・イタリア・スペイン・英国）
日本

調査期間：2020年～2034年

レポートハイライト

マンノースリン酸イソメラーゼ (MPI) 欠損症の市場は、疾患に対する認識の高まりと、医療支出の世界的増加により、今後数年間で変化を示すと考えられています。
企業や研究機関は、マンノースリン酸イソメラーゼ (MPI) 欠損症の研究開発に影響を与える可能性のある課題を分析し、その機会を探るべく取り組んでいます。開発中の治療薬は、病態を治療/改善するための新規アプローチに焦点を当てています。
大手企業はマンノースリン酸イソメラーゼ (MPI) 欠損症の治療薬の開発に取り組んでいます。新たな治療薬の上市は市場に大きな影響を与える見通しです。
マンノースリン酸イソメラーゼ (MPI) 欠損症の新規治療薬の開発には、疾患病態のより深い理解が必要です。
当社の開発段階ごと（第III相および第II相）のパイプラインアセットに関する詳細な分析、さまざまな新興動向、詳細な臨床プロファイル、主なクロスコンペティション、発売日、製品開発活動を含むパイプライン薬の比較分析は、研究開発活動の全体的なシナリオを特定することで、治療ポートフォリオに関する意思決定プロセスにおいてクライアントを支援します。

疫学：主要調査結果
前提・根拠：主要7カ国
疫学シナリオ：主要7カ国
- 主要7カ国におけるマンノースリン酸イソメラーゼ (MPI) 欠損症の疫学シナリオ：2020-2034年
疫学：米国
疫学：欧州5カ国
- ドイツ
- フランス
- イタリア
- スペイン
- 英国
疫学：日本

第8章治療アルゴリズム・現在の治療薬・医療行為

マンノースリン酸イソメラーゼ (MPI) 欠損症の治療と管理
マンノースリン酸イソメラーゼ (MPI) 欠損症の治療アルゴリズム

第9章アンメットニーズ

第10章マンノースリン酸イソメラーゼ (MPI) 欠損症治療の主なエンドポイント

第11章上市製品

主要7カ国の上市製品リスト
医薬品名・企業名
- 製品説明
- 規制のマイルストーン
- その他の開発活動
- 重要臨床試験
- 主要臨床試験の概要

第12章新興治療薬

主なクロスコンペティション
医薬品名・企業名
- 製品説明
- その他の開発活動
- 臨床開発
- 安全性と有効性
- 製品プロファイル

第13章マンノースリン酸イソメラーゼ (MPI) 欠損症：主要7カ国市場の分析

主要調査結果
主要7カ国の市場規模
主要7カ国の市場規模：治療薬別

第14章属性分析

第15章主要7カ国：市場の展望

米国：市場規模
欧州5カ国：市場規模・展望
ドイツ
フランス
イタリア
スペイン
英国
日本市場の展望

第16章マンノースリン酸イソメラーゼ (MPI) 欠損症：アクセスと償還の概要

第17章 KOLの見解

第18章市場促進要因

第19章市場の障壁

第20章付録

第21章 DelveInsightの能力

第22章免責事項

第23章 DelveInsightについて

図表

List of Tables

Table 1: 7MM Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology (2020-2034)
Table 2: 7MM Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases (2020-2034)
Table 3: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in the United States (2020-2034)
Table 4: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in the United States (2020-2034)
Table 5: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Germany (2020-2034)
Table 6: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Germany (2020-2034)
Table 7: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in France (2020-2034)
Table 8: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in France (2020-2034)
Table 9: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Italy (2020-2034)
Table 10: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Italy (2020-2034)
Table 11: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Spain (2020-2034)
Table 12: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Spain (2020-2034)
Table 13: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in the UK (2020-2034)
Table 14: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in the UK (2020-2034)
Table 15: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Japan (2020-2034)
Table 16: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Japan (2020-2034)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
Table 20: Region-wise Market Size in USD, Million (2020-2034)
Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
Table 22: United States Market Size in USD, Million (2020-2034)
Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
Table 24: Germany Market Size in USD, Million (2020-2034)
Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
Table 26: France Market Size in USD, Million (2020-2034)
Table 27: France Market Size by Therapy in USD, Million (2020-2034)
Table 28: Italy Market Size in USD, Million (2020-2034)
Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
Table 30: Spain Market Size in USD, Million (2020-2034)
Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
Table 32: United Kingdom Market Size in USD, Million (2020-2034)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
Table 34: Japan Market Size in USD, Million (2020-2034)
Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology (2020-2034)
Figure 2: 7MM Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases (2020-2034)
Figure 3: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in the United States (2020-2034)
Figure 4: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in the United States (2020-2034)
Figure 5: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Germany (2020-2034)
Figure 6: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Germany (2020-2034)
Figure 7: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in France (2020-2034)
Figure 8: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in France (2020-2034)
Figure 9: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Italy (2020-2034)
Figure 10: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Italy (2020-2034)
Figure 11: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Spain (2020-2034)
Figure 12: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Spain (2020-2034)
Figure 13: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in the UK (2020-2034)
Figure 14: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in the UK (2020-2034)
Figure 15: Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology in Japan (2020-2034)
Figure 16: Mannose Phosphate Isomerase (MPI) Deficiency Diagnosed and Treatable Cases in Japan (2020-2034)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
Figure 20: Region-wise Market Size in USD, Million (2020-2034)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
Figure 22: United States Market Size in USD, Million (2020-2034)
Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
Figure 24: Germany Market Size in USD, Million (2020-2034)
Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
Figure 26: France Market Size in USD, Million (2020-2034)
Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
Figure 28: Italy Market Size in USD, Million (2020-2034)
Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
Figure 30: Spain Market Size in USD, Million (2020-2034)
Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
Figure 34: Japan Market Size in USD, Million (2020-2034)
Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

Product Code: DIMI0676

DelveInsight's "Mannose Phosphate Isomerase (MPI) Deficiency - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Mannose Phosphate Isomerase (MPI) Deficiency, historical and forecasted epidemiology as well as the Mannose Phosphate Isomerase (MPI) Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Mannose Phosphate Isomerase (MPI) Deficiency market report provides current treatment practices, emerging drugs, Mannose Phosphate Isomerase (MPI) Deficiency market share of the individual therapies, current and forecasted Mannose Phosphate Isomerase (MPI) Deficiency market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Mannose Phosphate Isomerase (MPI) Deficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2020-2034

Mannose Phosphate Isomerase (MPI) Deficiency Disease Understanding and Treatment Algorithm

The DelveInsight Mannose Phosphate Isomerase (MPI) Deficiency market report gives a thorough understanding of the Mannose Phosphate Isomerase (MPI) Deficiency by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Mannose Phosphate Isomerase (MPI) Deficiency.

Treatment

It covers the details of conventional and current medical therapies available in the Mannose Phosphate Isomerase (MPI) Deficiency market for the treatment of the condition. It also provides Mannose Phosphate Isomerase (MPI) Deficiency treatment algorithms and guidelines in the United States, Europe, and Japan.

Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology

The Mannose Phosphate Isomerase (MPI) Deficiency epidemiology division provide insights about historical and current Mannose Phosphate Isomerase (MPI) Deficiency patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Mannose Phosphate Isomerase (MPI) Deficiency epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology

The epidemiology segment also provides the Mannose Phosphate Isomerase (MPI) Deficiency epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Mannose Phosphate Isomerase (MPI) Deficiency Drug Chapters

Drug chapter segment of the Mannose Phosphate Isomerase (MPI) Deficiency report encloses the detailed analysis of Mannose Phosphate Isomerase (MPI) Deficiency marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Mannose Phosphate Isomerase (MPI) Deficiency clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Mannose Phosphate Isomerase (MPI) Deficiency treatment.

Mannose Phosphate Isomerase (MPI) Deficiency Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Mannose Phosphate Isomerase (MPI) Deficiency treatment.

Mannose Phosphate Isomerase (MPI) Deficiency Market Outlook

The Mannose Phosphate Isomerase (MPI) Deficiency market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Mannose Phosphate Isomerase (MPI) Deficiency market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Mannose Phosphate Isomerase (MPI) Deficiency market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Mannose Phosphate Isomerase (MPI) Deficiency market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Mannose Phosphate Isomerase (MPI) Deficiency market in 7MM.

The United States Market Outlook

This section provides the total Mannose Phosphate Isomerase (MPI) Deficiency market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Mannose Phosphate Isomerase (MPI) Deficiency market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Mannose Phosphate Isomerase (MPI) Deficiency market size and market size by therapies in Japan is also mentioned.

Mannose Phosphate Isomerase (MPI) Deficiency Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Mannose Phosphate Isomerase (MPI) Deficiency market or expected to get launched in the market during the study period 2020-2034. The analysis covers Mannose Phosphate Isomerase (MPI) Deficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Mannose Phosphate Isomerase (MPI) Deficiency Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Mannose Phosphate Isomerase (MPI) Deficiency key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Mannose Phosphate Isomerase (MPI) Deficiency emerging therapies.

Reimbursement Scenario in Mannose Phosphate Isomerase (MPI) Deficiency

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Mannose Phosphate Isomerase (MPI) Deficiency domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Mannose Phosphate Isomerase (MPI) Deficiency market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Mannose Phosphate Isomerase (MPI) Deficiency Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Mannose Phosphate Isomerase (MPI) Deficiency, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Mannose Phosphate Isomerase (MPI) Deficiency epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Mannose Phosphate Isomerase (MPI) Deficiency are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Mannose Phosphate Isomerase (MPI) Deficiency market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Mannose Phosphate Isomerase (MPI) Deficiency market

Report Highlights:

In the coming years, Mannose Phosphate Isomerase (MPI) Deficiency market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Mannose Phosphate Isomerase (MPI) Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Mannose Phosphate Isomerase (MPI) Deficiency. Launch of emerging therapies will significantly impact the Mannose Phosphate Isomerase (MPI) Deficiency market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Mannose Phosphate Isomerase (MPI) Deficiency
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Mannose Phosphate Isomerase (MPI) Deficiency Report Insights

Patient Population
Therapeutic Approaches
Mannose Phosphate Isomerase (MPI) Deficiency Pipeline Analysis
Mannose Phosphate Isomerase (MPI) Deficiency Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Mannose Phosphate Isomerase (MPI) Deficiency Report Key Strengths

11 Years Forecast
7MM Coverage
Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Mannose Phosphate Isomerase (MPI) Deficiency Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions:

Market Insights:

What was the Mannose Phosphate Isomerase (MPI) Deficiency market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Mannose Phosphate Isomerase (MPI) Deficiency total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Mannose Phosphate Isomerase (MPI) Deficiency market size during the forecast period (2024-2034)?
At what CAGR, the Mannose Phosphate Isomerase (MPI) Deficiency market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Mannose Phosphate Isomerase (MPI) Deficiency market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Mannose Phosphate Isomerase (MPI) Deficiency market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Mannose Phosphate Isomerase (MPI) Deficiency?
What is the historical Mannose Phosphate Isomerase (MPI) Deficiency patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Mannose Phosphate Isomerase (MPI) Deficiency in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Mannose Phosphate Isomerase (MPI) Deficiency?
Out of all 7MM countries, which country would have the highest prevalent population of Mannose Phosphate Isomerase (MPI) Deficiency during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Mannose Phosphate Isomerase (MPI) Deficiency treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency in the USA, Europe, and Japan?
What are the Mannose Phosphate Isomerase (MPI) Deficiency marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Mannose Phosphate Isomerase (MPI) Deficiency?
How many therapies are developed by each company for Mannose Phosphate Isomerase (MPI) Deficiency treatment?
How many are emerging therapies in mid-stage, and late stage of development for Mannose Phosphate Isomerase (MPI) Deficiency treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Mannose Phosphate Isomerase (MPI) Deficiency therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Mannose Phosphate Isomerase (MPI) Deficiency and their status?
What are the key designations that have been granted for the emerging therapies for Mannose Phosphate Isomerase (MPI) Deficiency?
What are the global historical and forecasted market of Mannose Phosphate Isomerase (MPI) Deficiency?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Mannose Phosphate Isomerase (MPI) Deficiency market
To understand the future market competition in the Mannose Phosphate Isomerase (MPI) Deficiency market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Mannose Phosphate Isomerase (MPI) Deficiency in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Mannose Phosphate Isomerase (MPI) Deficiency market
To understand the future market competition in the Mannose Phosphate Isomerase (MPI) Deficiency market

1. Key Insights

2. Executive Summary of Mannose Phosphate Isomerase (MPI) Deficiency

3. Competitive Intelligence Analysis for Mannose Phosphate Isomerase (MPI) Deficiency

4. Mannose Phosphate Isomerase (MPI) Deficiency: Market Overview at a Glance

4.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Share (%) Distribution in 2020
4.2. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Share (%) Distribution in 2034

5. Mannose Phosphate Isomerase (MPI) Deficiency: Disease Background and Overview

5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology and Patient Population

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
- 7.3.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
- 7.4.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
  - 7.5.1.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
  - 7.5.2.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
  - 7.5.3.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
  - 7.5.4.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
  - 7.5.5.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
  - 7.5.6.1. Mannose Phosphate Isomerase (MPI) Deficiency Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Mannose Phosphate Isomerase (MPI) Deficiency Treatment and Management
8.2. Mannose Phosphate Isomerase (MPI) Deficiency Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Mannose Phosphate Isomerase (MPI) Deficiency Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross
12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile

List to be continued in report

13. Mannose Phosphate Isomerase (MPI) Deficiency: Seven Major Market Analysis

13.1. Key Findings
13.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size in 7MM
13.3. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size
- 15.1.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in the United States
- 15.1.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
- 15.3.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in Germany
- 15.3.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in Germany
15.4. France Market Size
- 15.4.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in France
- 15.4.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in France
15.5. Italy Market Size
- 15.5.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in Italy
- 15.5.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in Italy
15.6. Spain Market Size
- 15.6.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in Spain
- 15.6.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in Spain
15.7. United Kingdom Market Size
- 15.7.1. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in the United Kingdom
- 15.7.2. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
- 15.8.1. Japan Market Size
- 15.8.2. Mannose Phosphate Isomerase (MPI) Deficiency Total Market Size in Japan
- 15.8.3. Mannose Phosphate Isomerase (MPI) Deficiency Market Size by Therapies in Japan

マンノースリン酸イソメラーゼ (MPI) 欠損症：洞察・疫学・市場予測 (～2034年)

Mannose Phosphate Isomerase (MPI) Deficiency - Market Insight, Epidemiology, and Market Forecast - 2034

全表示

対象地域

レポートハイライト

目次

第1章 重要な洞察

第2章 マンノースリン酸イソメラーゼ (MPI) 欠損症：エグゼクティブサマリー

第3章 マンノースリン酸イソメラーゼ (MPI) 欠損症：競合分析

第4章 マンノースリン酸イソメラーゼ (MPI) 欠損症：市場概要

第5章 マンノースリン酸イソメラーゼ (MPI) 欠損症：疾患の背景・概要

第6章 ペイシェントジャーニー

第7章 マンノースリン酸イソメラーゼ (MPI) 欠損症：疫学・患者人口

第8章 治療アルゴリズム・現在の治療薬・医療行為

第9章 アンメットニーズ

第10章 マンノースリン酸イソメラーゼ (MPI) 欠損症治療の主なエンドポイント

第11章 上市製品

第12章 新興治療薬

第13章 マンノースリン酸イソメラーゼ (MPI) 欠損症：主要7カ国市場の分析

第14章 属性分析

第15章 主要7カ国：市場の展望

第16章 マンノースリン酸イソメラーゼ (MPI) 欠損症：アクセスと償還の概要